NASDAQ:IMRN Immuron (IMRN) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free IMRN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.41▼$2.4950-Day Range$4.80▼$5.6152-Week Range$1.92▼$28.99Volume3,424 shsAverage Volume21,339 shsMarket Capitalization$14.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesShort InterestSocial MediaStock AnalysisCompetitorsHeadlinesShort InterestSocial Media Get Immuron alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Immuron Stock (NASDAQ:IMRN)Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Read More Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy IMRN Stock News HeadlinesApril 15, 2024 | finance.yahoo.comImmuron Limited (IMRN) Interactive Stock Chart - Yahoo FinanceApril 15, 2024 | globenewswire.comImmuron to host Live Virtual EventApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 10, 2024 | finanznachrichten.deImmuron Limited: Immuron Travelan sales continued strong growthApril 10, 2024 | msn.comImmuron gains after Travelan sales updateApril 10, 2024 | globenewswire.comImmuron Travelan® sales continued strong growthMarch 27, 2024 | ca.finance.yahoo.comImmuron Limited (IMRN) Latest Stock News & Headlines - Yahoo FinanceMarch 22, 2024 | investing.comImmuron Ltd ADR (IMRN)April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 7, 2024 | msn.comImmuron surges after mid-stage data for antidiarrheal medMarch 7, 2024 | globenewswire.comImmuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the USMarch 7, 2024 | msn.comASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3February 22, 2024 | benzinga.comImmuron Stock (NASDAQ:IMRN) Dividends: History, Yield and DatesFebruary 21, 2024 | globenewswire.comImmuron Presentation Australian Biologics Festival 2024February 13, 2024 | finanznachrichten.deImmuron Limited: Immuron achieves record Travelan salesFebruary 13, 2024 | finance.yahoo.comImmuron achieves record Travelan® salesJanuary 16, 2024 | finanznachrichten.deImmuron Limited: Immuron achieves record half yearly Travelan salesJanuary 16, 2024 | finance.yahoo.comImmuron achieves record half yearly Travelan® salesJanuary 15, 2024 | msn.comASX Health Stocks: Immuron chalks up record half for travelers’ diarrhoea medicine, TravelanJanuary 15, 2024 | au.investing.comImmuron chalks up stellar half-year Travelan sales as travel returns to pre-pandemic levelsDecember 22, 2023 | finance.yahoo.comImmuron Clinical Trials UpdateDecember 4, 2023 | proactiveinvestors.comImmuron enrols first patients in Campylobacter Challenge clinical studyDecember 4, 2023 | markets.businessinsider.comImmuron Announces First Patients Enrolled in Campylobacter Challenge Clinical StudyNovember 28, 2023 | finance.yahoo.comImmuron CEO, Steven Lydeamore Investor Webinar PresentationNovember 13, 2023 | finance.yahoo.comImmuron CEO Steven Lydeamore Investor Webinar PresentationNovember 1, 2023 | au.investing.comImmuron receives bull case valuation of A$0.35 from Pitt Street ResearchOctober 31, 2023 | proactiveinvestors.comImmuron receives bull case valuation of A$0.35 from Pitt Street...See More Headlines Receive IMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMRN CUSIPN/A CIK1660046 Webwww.immuron.com.au Phone(138) 892-4854Fax6103 98227735EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.52 Quick Ratio7.79 Sales & Book Value Annual Sales$1.22 million Price / Sales11.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book1.07Miscellaneous Outstanding Shares5,700,000Free Float5,300,000Market Cap$14.19 million OptionableNot Optionable Beta1.43 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Jerry Kanellos Ph.D. (Age 60)CEO & COO Comp: $189.27kMr. Peter Anastasiou (Age 61)Exec. Vice Chairman Comp: $29.02kMr. Phillip Allen Hains (Age 62)CFO & Company Sec. Mr. David LyonHead of MarketingDr. Dan Ruben Peres (Age 45)Chief Medical Officer Key CompetitorsEdesa BiotechNASDAQ:EDSAABVC BioPharmaNASDAQ:ABVCNeuroBo PharmaceuticalsNASDAQ:NRBOTraws PharmaNASDAQ:TRAWAytu BioPharmaNASDAQ:AYTUView All Competitors IMRN Stock Analysis - Frequently Asked Questions Are investors shorting Immuron? Immuron saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 24,400 shares, a decrease of 5.1% from the March 31st total of 25,700 shares. Based on an average daily volume of 876,000 shares, the days-to-cover ratio is presently 0.0 days. View Immuron's Short Interest. What other stocks do shareholders of Immuron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immuron investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), CRISPR Therapeutics (CRSP), Dynavax Technologies (DVAX), OPKO Health (OPK), AbbVie (ABBV) and Co-Diagnostics (CODX). When did Immuron IPO? Immuron (IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager. This page (NASDAQ:IMRN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
